trending Market Intelligence /marketintelligence/en/news-insights/trending/Pikm_lhfGg4sf5p_lI0hAw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cancer Genetics to effect 1-for-30 reverse stock split to satisfy Nasdaq rule

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cancer Genetics to effect 1-for-30 reverse stock split to satisfy Nasdaq rule

Cancer Genetics Inc. is effecting a 1-for-30 reverse split of its outstanding common stock in order to comply with a Nasdaq listing rule.

The Rutherford, N.J.-based biotechnology company said the split is intended to raise the per share trading price of the company's common stock to satisfy the Nasdaq Capital Market's $1 minimum bid price requirement. The reverse split will reduce the number of the company's issued and outstanding common shares to about 2.1 million from about 63 million.

Cancer Genetics' common stock will continue to be traded on the Nasdaq Capital Market under the CGIX symbol.

The reverse split will also apply to the company's common stock issuable upon exercise of its outstanding warrants and stock options, subject to an adjustment in their exercise prices. The split will also apply to common stock issuable under Cancer Genetics' equity incentive plans.

The split will not work to change any stockholder's percentage interest in the company's equity, except to the extent that it results in some shareholders owning a fractional share. As no fractional shares will be issued in connection with the split, shareholders entitled to receive a fractional share will instead receive a cash payment based on the closing price of Cancer Genetics' common stock on Oct. 24.

Holders of a majority of the company's common shares approved the split on May 31, while Cancer Genetics' board approved the split at a ratio of 1-for-30 on Oct. 18.

Continental Stock Transfer & Trust Co. is acting as the exchange agent and transfer agent for the reverse stock split.

Cancer Genetics provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields.